Risk Factors for Hepatic Hydrothorax in Cirrhosis Patients with Ascites - A Clinical Cohort Study

被引:10
作者
Deleuran, Thomas [1 ,2 ]
Watson, Hugh [1 ,3 ]
Vilstrup, Hendrik [1 ]
Jepsen, Peter [1 ,4 ]
机构
[1] Aarhus Univ Hosp, Dept Gastroenterol & Hepatol, Palle Juul Jensens Blvd 99, DK-8200 Aarhus, Denmark
[2] Aalborg Univ Hosp, Dept Gastroenterol, Aalborg, Denmark
[3] Evotec ID, Lyon, France
[4] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark
关键词
Ascites; Cirrhosis; Diabetes; Hepatic hydrothorax; Non-selective beta-blockers; Portal hypertension; INTRAHEPATIC PORTOSYSTEMIC SHUNT; LONG-TERM; BETA-BLOCKERS; MANAGEMENT; ASSOCIATION; MODELS;
D O I
10.1007/s10620-021-07134-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The risk factors for hepatic hydrothorax are unknown. Methods We used data from three randomized trials of satavaptan treatment in patients with cirrhosis and ascites followed for up to 1 year. We excluded patients with previous hepatic hydrothorax or other causes for pleural effusion. The candidate risk factors were age, sex, heart rate, mean arterial pressure, diuretic-resistant ascites, a recurrent need for paracentesis, diabetes, hepatic encephalopathy, International Normalized Ratio, creatinine, bilirubin, albumin, sodium, platelet count, use of non-selective beta-blockers (NSBBs), spironolactone, furosemide, proton pump inhibitors, and insulin. We identified risk factors using a Fine and Gray regression model and backward selection. We reported subdistribution hazard ratios (sHR) for hepatic hydrothorax. Death without hepatic hydrothorax was a competing risk. Results Our study included 942 patients, of whom 41 developed hepatic hydrothorax and 65 died without having developed it. A recurrent need for paracentesis (sHR: 2.55, 95% CI: 1.28-5.08), bilirubin (sHR: 1.18 per 10 mu mol/l increase, 95% CI: 1.09-1.28), diabetes (sHR: 2.49, 95% CI: 1.30-4.77) and non-use of non-selective beta-blockers (sHR: 2.27, 95% CI: 1.13-4.53) were risk factors for hepatic hydrothorax. Development of hepatic hydrothorax was associated with a high mortality-hazard ratio of 4.35 (95% CI: 2.76-6.97). Conclusions In patients with cirrhosis and ascites, risk factors for hepatic hydrothorax were a recurrent need for paracentesis, a high bilirubin, diabetes and non-use of NSBBs. Among these patients with cirrhosis and ascites, development of hepatic hydrothorax increased mortality fourfold.
引用
收藏
页码:3395 / 3401
页数:7
相关论文
共 33 条
[1]  
Abbasi A, 2016, JCPSP-J COLL PHYSICI, V26, P566, DOI 2371
[2]   HEPATIC HYDROTHORAX - CAUSE AND MANAGEMENT [J].
ALBERTS, WM ;
SALEM, AJ ;
SOLOMON, DA ;
BOYCE, G .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (12) :2383-2388
[3]   Prognosis and prognostic research: validating a prognostic model [J].
Altman, Douglas G. ;
Vergouwe, Yvonne ;
Royston, Patrick ;
Moons, Karel G. M. .
BMJ-BRITISH MEDICAL JOURNAL, 2009, 338 :1432-1435
[4]   Hepatic Hydrothorax Clinical Features, Management, and Outcomes in 77 Patients and Review of the Literature [J].
Badillo, Ricardo ;
Rockey, Don C. .
MEDICINE, 2014, 93 (03) :135-142
[5]   Nonselective β-Blockers Do Not Affect Mortality in Cirrhosis Patients With Ascites: Post Hoc Analysis of Three Randomized Controlled Trials With 1198 Patients [J].
Bossen, Lars ;
Krag, Aleksander ;
Vilstrup, Hendrik ;
Watson, Hugh ;
Jepsen, Peter .
HEPATOLOGY, 2016, 63 (06) :1968-1976
[6]   BENIGN PLEURAL EFFUSIONS IN LONG-STANDING DIABETES-MELLITUS [J].
CHERTOW, BS ;
KADZIELAWA, R ;
BURGER, AJ .
CHEST, 1991, 99 (05) :1108-1111
[7]   Transjugular Intrahepatic Portosystemic Shunt for Symptomatic Refractory Hepatic Hydrothorax in Patients With Cirrhosis [J].
Dhanasekaran, Renumathy ;
West, Jonathan K. ;
Gonzales, Patrick C. ;
Subramanian, Ram ;
Parekh, Samir ;
Spivey, James R. ;
Martin, Louis G. ;
Kim, Hyun S. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (03) :635-641
[8]   Etiology and outcome of community-acquired pneumonia in patients with diabetes mellitus [J].
Falguera, K ;
Pifarre, R ;
Martin, A ;
Sheikh, A ;
Moreno, A .
CHEST, 2005, 128 (05) :3233-3239
[9]   A proportional hazards model for the subdistribution of a competing risk [J].
Fine, JP ;
Gray, RJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509
[10]  
Garbuzenko DV, 2017, WORLD J HEPATOL, V9, P1197, DOI 10.4254/wjh.v9.i31.1197